• 1
    Bonifacio E, Genovese S, Braghi S, et al. Islet autoantibody markers in insulin dependent diabetes: identification of screening strategies yielding high sensitivity. Diabetologia 1995; 38: 81622.
  • 2
    Bonifacio E, Lampasona V, Genovese S, Ferrari M, Bosi E. Identification of protein tyrosine phosphatase-like IA-2 (Islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol 1995; 155: 541926.
  • 3
    Bonifacio E, Lampasona V, Bingley PG. IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes mellitus associated tyrosine phosphate autoantigens. J Immunol 1998; 161: 264854.
  • 4
    Verge CF, Stenger D, Bonifacio E, et al. Combined use of autoantibodies (IA-2 autoantibody,GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes mellitus: combinatorial islet autoantibody workshop. Diabetes 1998; 47: 185766.
  • 5
    Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997; 350: 128893.
  • 6
    Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005; 48: 220612.
  • 7
    Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization and potential prevention. Diabetes Care 2001; 24: 14607.
  • 8
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27: S510.
  • 9
    Leslie RD, Williams R, Pozzilli P. Clinical review: type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006; 91: 16549.
  • 10
    Kobayashi T, Tamemoto K, Nakanishi K, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 1993; 16: 7808.
  • 11
    Nambam B, Aggarwal S, Jain A. Latent autoimmune diabetes in adults: a distinct but heterogeneous clinical entity. World J Diabetes 2010; 1: 1115.
  • 12
    Brophy S, Brunt H, Davies H, Mannan S, Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev 2007; 3: CD006165.
  • 13
    Buzzetti R, Di Pietro S, Giaccari A, et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 2007; 30: 932928.
  • 14
    Cervin C, Lyssenko V, Bakhtadze E, et al. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 2008; 57: 14337.
  • 15
    Carlsson S, Midthjell K, Grill V. Influence of family history of diabetes on incidence and prevalence of latent autoimmune diabetes of the adult: results from the Nord-Trøndelag Health Study. Diabetes Care 2007; 30: 30405.
  • 16
    Carlsson S, Midthjell K, Tesfamarian MY, Grill V. Age, overweight and physical inactivity increase the risk of latent autoimmune diabetes in adults: results from the Nord-Trøndelag Health Study. Diabetologia 2007; 50: 558.
  • 17
    Gale EAM. Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 2005; 48: 21959.
  • 18
    Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006; 29: 9705.
  • 19
    Naik RG, Palmer JP. Latent autoimmune diabetes in adults (LADA). Rev Endocr Metab Disord 2003; 4: 23341.
  • 20
    Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48: 1507.
  • 21
    Falorni A, Brozzetti A. Diabetes-related antibodies in adult diabetic patients. Best Pract Res Clin Endocrinol Metab 2005; 19: 11933.
  • 22
    Zinman B, Kahn SE, Haffner SM, O’Neill MC, Heise MA, Freed MI, ADOPT Study Group. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004; 53: 3193200.
  • 23
    Li X, Zhou Z, Huang G, Su H, Yan X, Yang L. Metabolic syndrome in adult-onset latent autoimmune diabetes. Metab Syndr Relat Disord 2005; 3: 17480.
  • 24
    Qi X, Sun J, Wang J, et al. Prevalence and correlates of latent autoimmune diabetes in adults in Tianjin, China: a population-based cross-sectional study. Diabetes Care 2011; 34: 6670.
  • 25
    Britten AC, Jones K, Törn C, et al. Latent autoimmune diabetes in adults in a South Asian population of the UK. Diabetes Care 2007; 30: 308890.
  • 26
    Maruyama T, Oak S, Shimada A, Hampe CS. GAD65 autoantibody responses in Japanese latent autoimmune diabetes in adult patients. Diabetes Care 2008; 31: 16027.
  • 27
    Ishii M, Hasegawa G, Fukui M, et al. Clinical and genetic characteristics of diabetic patients with high-titer (>10 000 U/ml) of antibodies to glutamic acid decarboxylase. Immunol Lett 2005; 99: 1805.
  • 28
    Petrone A, Park Y, Genovese S, et al. for the NIRAD Study Group and the Korean National Diabetes Program Similarities and differences between Caucasian and Asian LADA. Diabetologia 2008; 51: S155.
  • 29
    Roh MO, Jung CH, Kim BY, Mok JO, Kim CH. The prevalence and characteristics of latent autoimmune diabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea. Acta Diabetol 2010 Oct 16. [Epub ahead of print]
  • 30
    Lee SH, Kwon HS, Yoo SJ, et al. Identifying latent autoimmune diabetes in adults in Korea: the role of C-peptide and metabolic syndrome. Diabetes Res Clin Pract 2009; 83: e625.
  • 31
    Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta cell function in patients with type 1 diabetes in the diabetes control and complications trial: a randomized controlled trial. Ann Intern Med 1998; 128: 51723.
  • 32
    Davis TM, Wright AD, Mehta ZM, et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 2005; 48: 695702.
  • 33
    Malaisse WJ, Lebrun P. Mechanisms of sulfonylurea-induced insulin release. Diabetes Care 1990; 13: 917.
  • 34
    Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45: 6226.
  • 35
    Maruyama T, Tanaka S, Shimada A, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 2008; 93: 211521.
  • 36
    Argoud GM, Schade DS, Eaton RP. Insulin suppresses its own secretion in vivo. Diabetes 1987; 36: 95962.
  • 37
    Jansen A, Rosmalen JG, Homo-Delarche F, Dardenne M, Drexhage HA. Effect of prophylactic insulin treatment on the number of ER-MP23 macrophages in the pancreas of NOD mice: is the prevention of diabetes based on beta-cell rest? J Autoimmun 1996; 9: 3418.
  • 38
    Fuchtenbusch M, Kredel K, Bonifacio E, Schnell O, Ziegler AG. Exposure to exogenous insulin promotes IgG1 and the Thelper 2-associated IgG4 responses to insulin but not to other islet autoantigens. Diabetes 2000; 49: 91825.
  • 39
    Tiittanen M, Huupponen JT, Knip M, Vaarala O. Insulin treatment in patients with type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral blood mononuclear cells stimulated with insulin in vitro. Diabetes 2006; 55: 344654.
  • 40
    Schloot N, Eisenbarth GS. Isohormonal therapy of endocrine autoimmunity. Immunol Today 1995; 16: 28994.
  • 41
    Bertrand S, De Paepe M, Vigeant C, Yale JF. Prevention of adoptive transfer in BB rats by prophylactic insulin treatment. Diabetes 1992; 41: 12737.
  • 42
    Gotfredsen CF, Buschard K, Frandsen EK. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 1985; 8: 9335.
  • 43
    Kobayashi T. Multicenter prevention trial of slowly progressive IDDM with small dose of insulin (the Tokyo Study). Diabetes Metab Res Rev 2001; 17: S29.
  • 44
    Kobayashi T, Maruyama T, Shimada A, et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann NY Acad Sci 2002; 958: 11730.
  • 45
    Hanefeld M. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. Int J Clin Pract 2007; 61: 207.
  • 46
    Diani AR, Sawada G, Wyse B, Murray FT, Khan M. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004; 286: e11622.
  • 47
    Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 10219.
  • 48
    Holloway AC, Petrik JJ, Bruin JE, Gerstein HC. Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth. Diabetes Obes Metab 2008; 10: 76371.
  • 49
    Ghanaat-Pour H, Sjoholm A. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity. Diabete Metab Res Rev 2009; 25: 16384.
  • 50
    Cernea S, Buzzetti R, Pozzilli P. Beta cell protection and therapy for latent autoimmune diabetes in adults. Diabetes Care 2009; 32: S24652.
  • 51
    Zhou Z, Li X, Huang G, et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabete Metab Res Rev 2005; 21: 2038.
  • 52
    Gautier JF, Fetita S, Sobngwi E, Salau Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabete Metab 2005; 31: 23342.
  • 53
    Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both betacell replication and neogenesis, resulting in increased betacell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 22706.
  • 54
    Song WJ, Schreiber WE, Zhong E, et al. Exendin-4 stimulation of cyclin A2 in beta-cell proliferation. Diabetes 2008; 57: 237181.
  • 55
    Li Y, Cao X, Li LX, Brubaker PL, Edlund H, Drucker DJ. Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon- like peptide-1. Diabetes 2005; 54: 48291.
  • 56
    Dupre J. Glycaemic effects of incretins in type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept 2005; 128: 14957.
  • 57
    Spoletini M, Petrone A, Zampetti S, et al. Low-risk HLA genotype in type 1 diabetes is associated with less destruction of pancreatic B-cells 12 months after diagnosis. Diabet Med 2007; 24: 148790.
  • 58
    Birk OS, Elias D, Weiss AS, et al. NOD mouse diabetes: the ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells. J Autoimmun 1996; 9: 15966.
  • 59
    Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta cell function in new-onset type 1 diabetes and immune-modulation with a heat-shock protein peptide (Dia- Pep277): a randomised, doubleblind, phaseII trial. Lancet 2001; 358: 174953.
  • 60
    Raz I, Avron A, Tamir M, et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabete Metab Res Rev 2007; 23: 2928.
  • 61
    Pozzilli P, Guglielmi C. Immunomodulation for the prevention of SPIDDM and LADA. Ann N Y Acad Sci 2006; 1079: 908.
  • 62
    Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19: 23846.
  • 63
    Ludvigsson J, Faresjo M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359: 190920.
  • 64
    Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011; 378: 31927.